Innokas was selected as the manufacturing partner for Norwegian company Luzmon AS. Innokas has worked closely with Luzmon and their UK based R&D partner Plexus in offering manufacturability support to companies as they are finalizing the design of for the Luzmon’s cTEMS and cTENS system including some NPI and sourcing work. Innokas’ NPI team and engineers have e.g. evaluated the initial, clinically proved medical concept of the system and requirements with cost-efficient manufacturability rules.

‍

Luzmon Medical’s CEO Erlend Stromnes tells that the company has been very satisfied with the cooperation with Innokas and that the company chose Innokas as manufacturing partner especially because of Innokas’ strong references and the high-class quality factors. “Innokas was chosen through a careful selection process, of course, where competence, quality, implementation capacity and reference products was among the selected variables. After the evaluation made by Luzmon, Innokas turned out to be the best choice for us”, Stromnes states.

‍

The Luzmon cTEMS device is developed with the intended use of Improving health and performance by preservation, restoration and improvement of skeletal muscle. The company has made decades of research around TENS, EMS and thermal therapy, and the studies show that these therapies are very efficient for both prevention and rehabilitation of the human body. Luzmon has developed their proprietary system together with cooperation partners around Europe, and the system will be ready for actual manufacturing during the year of 2018.